Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Affect Disord ; 190: 162-166, 2016 Jan 15.
Article in English | MEDLINE | ID: mdl-26519636

ABSTRACT

BACKGROUND: Sleep disturbance in bipolar disorder (BD) is common during and between mood episodes. In recovered (euthymic at least two months) BD patients, we assessed sleep compared to controls and its relationships with residual mood symptoms and mood episode recurrence. METHOD: Recovered Stanford University BD Clinic patients diagnosed with the Systematic Treatment Enhancement Program for BD (STEP-BD) Affective Disorders Evaluation and monitored with the STEP-BD Clinical Monitoring Form (CMF) for >1 year and healthy controls completed the Pittsburgh Sleep Quality Index (PSQI). PSQI parameters were compared in BD patients versus controls, and the most robustly differentiating PSQI parameter was assessed in relationship to residual mood symptoms, and time to mood episode recurrence in BD patients. RESULTS: Eighty nine recovered BD patients compared to 56 healthy controls had significantly worse PSQI global score, more sleep medication use, longer sleep latency, and worse daytime dysfunction. PSQI global score had the greatest BD patient versus control effect size, and among BD patients, correlated significantly with residual mood symptoms and predicted earlier mood episode recurrence, even after covarying for residual mood symptoms. LIMITATIONS: Use of subjective (PSQI) rather objective (polysomnography) sleep metric. Statistical power limited by small sample size. Potential psychotropic medication confound. Northern California tertiary BD clinic referral sample. CONCLUSION: Further research is needed to confirm that in recovered BD patients, poor sleep quality correlates with residual mood symptoms, and independently predicts mood episode recurrence. If confirmed, these observations suggest potential mood benefit for focusing on sleep quality in interventions for recovered BD patients.


Subject(s)
Bipolar Disorder/epidemiology , Circadian Rhythm/physiology , Cyclothymic Disorder/epidemiology , Sleep Wake Disorders/epidemiology , Adult , Affect , Bipolar Disorder/psychology , California/epidemiology , Chronic Disease/epidemiology , Comorbidity , Cyclothymic Disorder/psychology , Female , Humans , Male , Middle Aged , Recurrence , Risk Factors , Sleep Wake Disorders/psychology
2.
Ann Clin Psychiatry ; 23(1): 17-24, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21318192

ABSTRACT

BACKGROUND: Lamotrigine and quetiapine are commonly used in bipolar disorder, but there are no published systematic studies of their use in combination for treatment-resistant bipolar depression. METHODS: We studied 39 trials in outpatients (15 with bipolar I disorder, 22 with bipolar II disorder, and 1 with bipolar disorder not otherwise specified; 1 patient had 2 trials) with depression resistant to quetiapine or lamotrigine who were taking a mean of 1.7 other prescription psychotropic medications. Patients were given either open-label lamotrigine or quetiapine naturalistically, for up to 12 weeks of combination therapy. RESULTS: Lamotrigine (mean dose, 204.2 mg/d) plus quetiapine (mean dose, 188.5 mg/d) increased the euthymia rate (0.0% to 46.2%), decreased syndromal (79.5% to 30.8%) and subsyndromal (20.5% to 15.4%) depression rates, and improved Clinical Global Impression-Severity (mean change, -1.0) and Global Assessment of Functioning (mean change, +5.9) scores. Approximately one-fifth of patients discontinued therapy (20.5%) or required subsequent additional pharmacotherapy (20.5%). Only 10.3% discontinued due to adverse effects, and there was no significant change in mean body weight. CONCLUSIONS: The findings of this uncontrolled open pilot study must be viewed with caution. However, randomized, double-blind, placebo-controlled studies are warranted to confirm the possibility that combination therapy with lamotrigine and quetiapine is effective and well tolerated in patients with treatment-resistant bipolar depression.


Subject(s)
Affect/drug effects , Bipolar Disorder , Dibenzothiazepines , Drug Resistance , Triazines , Adult , Antimanic Agents/administration & dosage , Antimanic Agents/adverse effects , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/adverse effects , Bipolar Disorder/diagnosis , Bipolar Disorder/drug therapy , Bipolar Disorder/physiopathology , Bipolar Disorder/psychology , Diagnostic and Statistical Manual of Mental Disorders , Dibenzothiazepines/administration & dosage , Dibenzothiazepines/adverse effects , Drug Therapy, Combination , Female , Humans , Interview, Psychological , Lamotrigine , Male , Middle Aged , Monitoring, Physiologic , Pilot Projects , Psychiatric Status Rating Scales , Quetiapine Fumarate , Severity of Illness Index , Treatment Outcome , Triazines/administration & dosage , Triazines/adverse effects , Xerostomia/chemically induced
3.
J Psychiatr Res ; 44(14): 921-9, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20378127

ABSTRACT

OBJECTIVE: To assess quetiapine effectiveness in bipolar disorder (BD) patients in a clinical setting. METHODS: We naturalistically administered open quetiapine to outpatients assessed with the Systematic Treatment Enhancement Program for BD (STEP-BD) Affective Disorders Evaluation, and monitored longitudinally with the STEP-BD Clinical Monitoring Form. RESULTS: 96 patients (36 BD I, 50 BD II, 9 BD NOS, 1 Schizoaffective Bipolar Type, mean ± SD age 42.3 ± 13.8 years, 66.7% female) received quetiapine, combined with an average of 2.5 (in 66.7% of patients at least 2) other psychotropic medications and 0.9 non-psychotropic medications, started most often during depressive symptoms (53.1%) or euthymia (37.5%). Mean quetiapine duration and final dose were 385 days and 196 mg/day (50.0% of patients took ≤75 mg/day). Quetiapine was discontinued in 38.5% of trials, after on average 307 days, most often (in 19.8%) due to CNS adverse effects (primarily sedation). In 38.5% of trials quetiapine was continued on average 328 days with no subsequent psychotropic added. In 22.9% quetiapine was continued on average 613 days, but had subsequent psychotropic added after on average 113 days, most often for depressive symptoms. In 67 trials started at Stanford, quetiapine tended to primarily maintain euthymia and relieve depressive symptoms. In 29 trials started prior to Stanford, continuing quetiapine tended to primarily maintain euthymia and relieve mood elevation symptoms. Aside from sedation, quetiapine was generally well tolerated. CONCLUSIONS: In bipolar disorder outpatients quetiapine had a moderate (38.5%, with 385-day mean duration) discontinuation rate, and commonly did not require subsequent additional pharmacotherapy, suggesting effectiveness in a clinical setting.


Subject(s)
Antipsychotic Agents/administration & dosage , Bipolar Disorder/drug therapy , Depression/drug therapy , Dibenzothiazepines/administration & dosage , Adult , Antipsychotic Agents/adverse effects , Bipolar Disorder/diagnosis , Bipolar Disorder/psychology , Diagnostic and Statistical Manual of Mental Disorders , Dibenzothiazepines/adverse effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Female , Humans , Longitudinal Studies , Male , Middle Aged , Outpatients , Psychiatric Status Rating Scales , Psychotropic Drugs/administration & dosage , Quetiapine Fumarate , Time Factors , Treatment Outcome
4.
Bipolar Disord ; 11(3): 330-6, 2009 May.
Article in English | MEDLINE | ID: mdl-19419390

ABSTRACT

OBJECTIVES: Bipolar disorder is associated with positive emotion disturbance, though it is less clear which specific positive emotions are affected. METHODS: The present study examined differences among distinct positive emotions in recovered bipolar disorder (BD) patients (n = 55) and nonclinical controls (NC) (n = 32) and whether they prospectively predicted symptom severity in patients with BD. At baseline, participants completed self-report measures of several distinct trait positive emotions. Structured assessments of diagnosis and current mood symptoms were obtained for BD participants. At a six-month follow-up, a subset of BD participants' (n = 39) symptoms were reassessed. RESULTS: BD participants reported lower joy, compassion, love, awe, and contentment compared to NC participants. BD and NC participants did not differ in pride or amusement. For BD participants, after controlling for baseline symptom severity, joy and amusement predicted increased mania severity, and compassion predicted decreased mania severity at the six-month follow-up. Furthermore, amusement predicted increased depression severity and pride predicted decreased severity of depression. Awe, love, and contentment did not predict symptom severity. CONCLUSIONS: These results are consistent with a growing literature highlighting the importance of positive emotion in the course of bipolar disorder.


Subject(s)
Bipolar Disorder/diagnosis , Bipolar Disorder/physiopathology , Emotions/physiology , Adult , Female , Humans , Male , Middle Aged , Prospective Studies , Psychiatric Status Rating Scales
5.
J Psychiatr Res ; 43(1): 13-23, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18423667

ABSTRACT

OBJECTIVE: To assess lamotrigine effectiveness in bipolar disorder (BD) patients in a clinical setting. METHOD: Open lamotrigine was naturalistically administered to outpatients at the Stanford University BD Clinic assessed with the Systematic Treatment Enhancement Program for BD (STEP-BD) Affective Disorders Evaluation, and monitored longitudinally with the STEP-BD Clinical Monitoring Form. RESULTS: One hundred and ninety-seven patients (64 BD I, 110 BD II, 21 BD NOS, 2 Schizoaffective Bipolar Type, mean+/-SD age 42.2+/-14.4 years, 62% female) had 200 trials of lamotrigine. Lamotrigine was combined with a mean of 2.1+/-1.5 other psychotropic medications, most often during euthymia or depressive symptoms. Mean lamotrigine duration was 434+/-444 days, and mean final dose was 236+/-132mg/day without valproate, and 169+/-137mg/day with valproate. Lamotrigine was discontinued in only 26.5% of trials at 255+/-242 days, most often due to inefficacy, and seldom due to adverse effects. In 31.5% of trials lamotrigine was continued 264+/-375 days with no subsequent psychotropic added. In 42.0% of trials lamotrigine was continued 674+/-479 days, but had subsequent psychotropic added at 146+/-150 days, most often for anxiety/insomnia and depressive symptoms. In 145 trials started at Stanford, lamotrigine primarily yielded relief of depressive symptoms or maintained euthymia. In 55 trials in which lamotrigine was started prior to Stanford, lamotrigine primarily maintained euthymia. Lamotrigine was generally well tolerated, with no serious rash, and only 3.5% discontinuing due to benign rash. CONCLUSION: In a cohort of bipolar disorder outpatients commonly with comorbid conditions, and most often receiving complex combination therapy, lamotrigine had a low (26.5%, with an overall mean duration of treatment of 434 days) discontinuation rate, suggesting effectiveness in BD in a clinical setting.


Subject(s)
Anticonvulsants/therapeutic use , Bipolar Disorder/drug therapy , Triazines/therapeutic use , Adult , Ambulatory Care , Antimanic Agents/therapeutic use , Bipolar Disorder/diagnosis , Bipolar Disorder/psychology , Clinical Protocols , Cohort Studies , Comorbidity , Diagnostic and Statistical Manual of Mental Disorders , Drug Administration Schedule , Drug Resistance , Drug Therapy, Combination , Female , Humans , Lamotrigine , Longitudinal Studies , Male , Patient Dropouts , Psychiatric Status Rating Scales , Psychotic Disorders/drug therapy , Psychotropic Drugs/therapeutic use , Treatment Outcome
6.
Psychiatr Serv ; 58(1): 41-8, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17215411

ABSTRACT

OBJECTIVE: Little is known about the factors contributing to mental illness stigma among caregivers of people with bipolar disorder. METHODS: A total of 500 caregivers of patients participating in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study were interviewed in a cross-sectional design on measures of stigma, mood, burden, and coping. Relatives and friends with bipolar disorder were assessed on measures of diagnosis and clinical status, determined by a days-well measure derived from psychiatrist ratings of DSM-IV episode status. Because patients' clinical status varied widely, separate models were run for patients who were euthymic for at least three-fourths of the past year (well group) and for those who met criteria for an affective episode for at least one-fourth of the previous year (unwell group). Stepwise multiple regression was used to identify patient, illness, and caregiver characteristics associated with caregiver stigma. RESULTS: In the unwell group, greater mental illness stigma was associated with bipolar I (versus II) disorder, less social support for the caregiver, fewer caregiver social interactions, and being a caregiver of Hispanic descent. In the well group, greater stigma was associated with being a caregiver who is the adult child of a parent with bipolar disorder, who has a college education, who has fewer social interactions, and who cares for a female bipolar patient. CONCLUSIONS: Mental illness stigma was found to be prevalent among caregivers of persons with bipolar disorder who have active symptoms as well as for caregivers of those who have remitted symptoms. Stigma is typically associated with factors identifying patients as "different" during symptomatic periods. Research is needed to understand how the stigma experienced by caregivers during stable phases of illness differs from the stigma experienced during patients' illness states.


Subject(s)
Bipolar Disorder/psychology , Bipolar Disorder/therapy , Caregivers/psychology , Caregivers/statistics & numerical data , Depression/epidemiology , Depression/psychology , Health Promotion , Stereotyping , Adolescent , Adult , Aged , Cost of Illness , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Psychology , Severity of Illness Index , Social Support
7.
Ann Clin Psychiatry ; 18(3): 169-72, 2006.
Article in English | MEDLINE | ID: mdl-16923655

ABSTRACT

BACKGROUND: There are limited management options for treatment-resistant depression in bipolar disorder (BD) patients. METHOD: Open adjunctive aripiprazole was administered to outpatients with treatment-resistant depression assessed with the Systematic Treatment Enhancement Program for BD (STEP-BD) Affective Disorders Evaluation, and followed with the STEP-BD Clinical Monitoring Form. RESULTS: Thirty BD (11 type I, 15 type II, 4 NOS) patients (mean age 44.4 +/- 17.0 years, 70% female) on a mean of 3.2 +/- 1.6 other psychotropic and 2.3 +/- 1.6 nonpsychotropic prescription medications received aripiprazole for a mean duration of 84 +/- 69 days, with a mean final dose of 15.3 +/- 11.2 (range 2.5-40) mg/day. Fourteen patients (47%) discontinued aripiprazole; due to inefficacy in 5/30 (17%), patient choice in 3/30 (10%), and adverse effects in 6/30 (20%). Aripiprazole yielded improvement in Clinical Global Impression-Severity (CGI-S, 4.4 +/- 1.1 to 3.8 +/- 1.2, p < 0.01), with 8/30 (27%) patients responding (CGI-S improvement > or = 2), including 4/30 (13%) who remitted (final CGI-S < or = 2). Global Assessment of Function, and depressed mood and suicidal ideation ratings also improved. Aripiprazole was generally well tolerated, with no significant change in mean adverse effect ratings or mean weight. CONCLUSION: Aripiprazole appeared effective and generally well tolerated in treatment-resistant bipolar depression. Controlled trials are warranted to systematically explore these preliminary naturalistic observations.


Subject(s)
Antipsychotic Agents/administration & dosage , Bipolar Disorder/drug therapy , Piperazines/administration & dosage , Quinolones/administration & dosage , Adult , Ambulatory Care , Antipsychotic Agents/adverse effects , Aripiprazole , Bipolar Disorder/diagnosis , Bipolar Disorder/psychology , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Resistance , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Personality Assessment , Piperazines/adverse effects , Prospective Studies , Quinolones/adverse effects , Treatment Outcome
8.
Psychooncology ; 11(6): 495-504, 2002.
Article in English | MEDLINE | ID: mdl-12476431

ABSTRACT

This study examined coping and distress in African American (n=8), Hispanic (n=53), and non-Hispanic White (n=70) women with early stage breast cancer. The participants were studied prospectively across a year beginning at the time of surgery. African American women reported the lowest levels of distress (particularly before surgery) and depression symptoms. Hispanic women reported the highest levels of self-distraction as a coping response, non-Hispanic Whites reported the highest use of humor. Hispanics reported the highest levels of venting, African Americans reported the lowest levels. African American and Hispanic women reported more religious coping than non-Hispanic Whites. The data also provided evidence of a maladaptive spiral of distress and avoidant coping over time. Although some ethnic differences were identified, findings also point to a great many similarities across groups.


Subject(s)
Adaptation, Psychological , Black or African American/psychology , Breast Neoplasms/psychology , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/etiology , Hispanic or Latino/psychology , White People/psychology , Adult , Black or African American/statistics & numerical data , Aged , Aged, 80 and over , Depressive Disorder, Major/psychology , Female , Hispanic or Latino/statistics & numerical data , Humans , Male , Middle Aged , Neoplasm Staging , White People/statistics & numerical data
SELECTION OF CITATIONS
SEARCH DETAIL
...